Prothena Corp. (Nasdaq: PRTA) reported positive results from a Phase 1
study of its Parkinson's disease treatment PRX002 sending the stock
price soaring $11.17 to $40.40.
Positive study results for Prothena
March 20, 2015 at 11:39 AM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.